Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
April 05, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
April 03, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
March 07, 2024 15:23 ET | PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
March 05, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
February 20, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
December 20, 2023 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
lipella logo.png
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment
May 10, 2022 15:27 ET | Lipella Pharmaceuticals, Inc.
Pittsburgh, Pennsylvania, United States , May 10, 2022 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program...